In this Aug. 14, 2020, file photo, laboratory technicians work at the mAbxience biopharmaceutical company on an experimental coronavirus vaccine developed by Oxford University and the laboratory AstraZeneca in Garin, Argentina. AstraZeneca announced Monday, Aug. 31, its vaccine candidate has entered the final testing stage in the U.S. (AP Photo/Natacha Pisarenko, File)
(WASHINGTON AP) – A third leading candidate COVID-19 vaccine has entered a final stage of human testing in the United States. AstraZeneca announced Monday its potential COVID-19 vaccine has entered final trials in the U.S. to test the effectiveness and safety of the product. The Cambridge, England-based company said the trial will involve up to 30,000 adults from various racial, ethnic and geographic groups. The potential vaccine was invented by the University of Oxford and an associated company, Vaccitech. Meanwhile, a U.S. advisory panel is suggesting a way to ration the first limited doses once a vaccine does prove safe and effective.
Click here for more information.